Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
NRG Oncology
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05050084CT.gov Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial | — | Active Not Recruiting | — | — | — |
NCT04513717CT.gov Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial | — | Active Not Recruiting | — | — | — |
NCT03678025CT.gov Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT02278185CT.gov Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer | — | Completed | — | — | — |
NCT01394263CT.gov Study of Histrelin Subdermal Implant in Patients With Prostate Cancer | — | Completed | — | — | — |
NCT01697384CT.gov Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Histrelin (this asset) | NRG Oncology | P3 | BB · 68 |
| Docetaxel | Instituto do Cancer do Estado de São Paulo | P3 | BBB |
| Degarelix | Canadian Cancer Trials Group | P3 | BB |
| Nilutamide | SWOG Cancer Research Network | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2 | BB |
| Prednisone | Mayo Clinic | P3 | BB |
| Leuporelin | Mayo Clinic | P3 | BB |
| Goserelin | CancerCare Manitoba | P3 | BB |
| Lidocaine | Bagcilar Training and Research Hospital | P4 | BB |
+42 more in the Prostate Adenocarcinoma cohort
Other indications for Histrelin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Cancer | — | P3 | BB · 64 |
| Hypogonadism | — | P3 | B · 60 |
| Prostate Carcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Histrelin in Prostate Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/histrelin-prostate-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →